Know Cancer

forgot password

A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia

Phase 2
18 Years
Open (Enrolling)
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia

Thank you

Trial Information

A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia

Inclusion Criteria:

1. Metastatic or unresectable adenocarcinoma of the upper gastrointestinal tract that
can be measured in at least one dimension according to RECIST criteria by CT or MRI

2. Gastric adenocarcinomas may be included if the primary tumor arises within 5 cm of
the anatomic gastro-esophageal junction (distal esophagus) or from the gastric cardia
as indicated by either endoscope or imaging.

3. Previously untreated with chemotherapeutic agents for unresectable or metastatic

4. Adjuvant chemotherapy and/or radiotherapy are allowed as long as no oxaliplatin was
used in the past 12 months.

5. ECOG performance status 0 or 1

6. Age > 18 years old.

7. Life expectancy greater than 6 months.

8. Peripheral neuropathy: must be < grade 1

9. Absolute neutrophil count > 1,500/mm3

10. Hemoglobin > 9.0 g/dl

11. Platelet count > 100,000/mm3

12. Hepatic Function:

1. Total Bilirubin < or = to 1.5 x ULN

2. AST and ALT must be < or = to 3.0 x ULN (< or = to 5.0 x ULN if there is liver

13. Creatinine clearance of > 60 ml/min as calculated by the Cockcroft Gault formula.
(Ccr = ((140-Age) X Wt (kg))/ (72 X SCr (mg/100ml) for males).

(Ccr = ((140-Age) X Wt (kg))/ (72 X SCr (mg/100ml) x 0.85 for females)

14. Women of childbearing potential must have a negative pregnancy test by urine or serum

15. Men and women of childbearing potential must be willing to consent to using effective
contraception while on treatment and for at least 4 months after the last treatment.

16. Patients must have signed IRB approved informed consent

17. Patients must have the ability to comply with study and follow-up procedures.

Exclusion Criteria:

1. Patients with known hypersensitivity to any components of oxaliplatin, leucovorin,
5-fluorouracil (or other fluoropyrimidines) or erlotinib.

2. Women who are breast-feeding or pregnant.

3. Presence of > Grade 2 neuropathy

4. Patients with prior malignancy other than non-melanoma skin cancer or cervical
carcinoma in situ within the past five years

5. Current or prior history of central nervous system or brain metastases

6. Any other medical conditions, which, in the opinion of the investigator, would
preclude subjects to participate in the study.

7. Patients who have received chemotherapy, surgery or radiation therapy within 30 days
prior to the first dose.

8. INR greater than 3.5 for patients on warfarin

9. Known HIV infection

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the overall response rate of previously-untreated patients with unresectable or metastatic adenocarcinomas of the upper gastrointestinal tract when treated with the combination of 5-fluorouracil, leucovorin, oxaliplatin, and erlotinib.

Outcome Time Frame:

5 years

Safety Issue:


Principal Investigator

Zev Wainberg, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, Los Angeles


United States: Food and Drug Administration

Study ID:




Start Date:

April 2008

Completion Date:

Related Keywords:

  • Unresectable Adenocarcinoma of the Esophagus
  • Metastatic Adenocarcinoma of the Esophagus
  • Unresectable Adenocarcinoma of Gastric Cardia
  • Metastatic Adenocarcinoma of Gastric Cardia
  • Unresectable
  • Metastatic
  • Esophagus
  • Gastric Cardia
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Esophageal Neoplasms



UCLA Jonsson Comprehensive Cancer Center Los Angeles, California  90095
Translational Oncology Research International (TORI) Network Los Angeles, California  90095